ORIC PHARMACEUTICALS INC (ORIC) Stock Price, Quote, News and Overview
NASDAQ:ORIC - Nasdaq - US68622P1093 - Common Stock - Currency: USD
ORIC Quote, Performance and Key Statistics
9.93
+0.1 (+1.02%)
The current stock price of ORIC is 9.93 USD. In the past month the price decreased by -10.86%. In the past year, price increased by 6.77%.
ORIC Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.33 | 361.55B | ||
| AMGN | AMGEN INC | 13.31 | 156.09B | ||
| GILD | GILEAD SCIENCES INC | 15.38 | 148.05B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.04 | 100.23B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.4 | 61.11B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 57.73B | ||
| ARGX | ARGENX SE - ADR | 70.38 | 39.93B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.7 | 33.51B | ||
| BNTX | BIONTECH SE-ADR | N/A | 27.09B | ||
| INSM | INSMED INC | N/A | 24.24B | ||
| NTRA | NATERA INC | N/A | 21.63B | ||
| BIIB | BIOGEN INC | 8.43 | 19.77B |
Related stock screener links
About ORIC
Company Profile
Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. The company is headquartered in South San Francisco, California and currently employs 115 full-time employees. The company went IPO on 2020-04-24. The firm is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. The firm's clinical-stage product candidates include ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer, and ORIC-114, a brain penetrant inhibitor that selectively targets EGFR exon 20, HER2 exon 20 and EGFR atypical mutations, being developed across multiple genetically defined cancers. In addition, the Company is also developing multiple discovery stage precision medicines targeting other hallmark cancer resistance mechanisms. Its out-licensing candidates include ORIC-533 and ORIC-613.
Company Info
ORIC PHARMACEUTICALS INC
240 E. Grand Ave, 2nd Floor
South San Francisco CALIFORNIA 94080 US
CEO: Jacob M. Chacko
Employees: 115
Phone: 16503885600
ORIC PHARMACEUTICALS INC / ORIC FAQ
What is the stock price of ORIC PHARMACEUTICALS INC today?
The current stock price of ORIC is 9.93 USD. The price increased by 1.02% in the last trading session.
What is the ticker symbol for ORIC PHARMACEUTICALS INC stock?
The exchange symbol of ORIC PHARMACEUTICALS INC is ORIC and it is listed on the Nasdaq exchange.
On which exchange is ORIC stock listed?
ORIC stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for ORIC PHARMACEUTICALS INC stock?
18 analysts have analysed ORIC and the average price target is 18.77 USD. This implies a price increase of 89% is expected in the next year compared to the current price of 9.93. Check the ORIC PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is ORIC PHARMACEUTICALS INC worth?
ORIC PHARMACEUTICALS INC (ORIC) has a market capitalization of 846.23M USD. This makes ORIC a Small Cap stock.
How many employees does ORIC PHARMACEUTICALS INC have?
ORIC PHARMACEUTICALS INC (ORIC) currently has 115 employees.
What are the support and resistance levels for ORIC PHARMACEUTICALS INC (ORIC) stock?
ORIC PHARMACEUTICALS INC (ORIC) has a support level at 9.53 and a resistance level at 9.94. Check the full technical report for a detailed analysis of ORIC support and resistance levels.
Should I buy ORIC PHARMACEUTICALS INC (ORIC) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of ORIC, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of ORIC, evaluating the profitability, health, valuation and growth aspects
- ORIC PHARMACEUTICALS INC (ORIC) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- ORIC PHARMACEUTICALS INC (ORIC) Sales and EPS estimates to see what analysts future expectations are.
- ORIC PHARMACEUTICALS INC (ORIC) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- ORIC PHARMACEUTICALS INC (ORIC) Insider and Institutional Ownership to learn about the owners and their transactions.
- ORIC PHARMACEUTICALS INC (ORIC) Stock Chart to make your own analysis
- ORIC PHARMACEUTICALS INC (ORIC) Latest news and press-releases to stay up to date.
Does ORIC PHARMACEUTICALS INC (ORIC) stock pay dividends?
ORIC does not pay a dividend.
When does ORIC PHARMACEUTICALS INC (ORIC) report earnings?
ORIC PHARMACEUTICALS INC (ORIC) will report earnings on 2025-11-10.
What is the Price/Earnings (PE) ratio of ORIC PHARMACEUTICALS INC (ORIC)?
ORIC PHARMACEUTICALS INC (ORIC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.89).
What is the Short Interest ratio of ORIC PHARMACEUTICALS INC (ORIC) stock?
The outstanding short interest for ORIC PHARMACEUTICALS INC (ORIC) is 16.1% of its float. Check the ownership tab for more information on the ORIC short interest.
ORIC Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to ORIC. When comparing the yearly performance of all stocks, ORIC is one of the better performing stocks in the market, outperforming 93.55% of all stocks.
ORIC Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ORIC. No worries on liquidiy or solvency for ORIC as it has an excellent financial health rating, but there are worries on the profitability.
ORIC Financial Highlights
Over the last trailing twelve months ORIC reported a non-GAAP Earnings per Share(EPS) of -1.89. The EPS decreased by -8% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -54.71% | ||
| ROE | -60.46% | ||
| Debt/Equity | 0 |
ORIC Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 89% to ORIC. The Buy consensus is the average rating of analysts ratings from 18 analysts.